The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein R.sup.A and R.sup.B are as defined herein. Tumors can be imaged or targeted for therapeutic treatment using compounds described herein where at least one R.sup.A or at least one R.sup.B group comprises a imaging agent, a therapeutic agent, or a member of a specific binding pair which can be associated with a secondary imaging agent, such as a microbubble for ultrasonic imaging. ##STR00001##

Cyclic D,L--peptides were shown to have an anti-amyloid aggregation effect. The cyclic peptide (designated cyclic peptide-2) having the sequence [1JwHsK], had a drastic effect on amyloid aggregation. However, the linear equivalent of cyclic peptide-2 did not inhibit amyloid formation. Cyclic peptide 2 was also effective in reducing A-induced toxicity in PC12 cells. According to embodiments of the invention, cyclic peptides may comprise between 6 or 8 amino acids. In an embodiment, half of the amino acid residues are in the D-formation, and the other half are in the L-formation. In an embodiment of the invention, the amino acids alternate between the D and L-formations.

An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody.

The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.

Compositions, methods of making, and methods of using, xenoantigen-displaying anti-cancer vaccines are described.

A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized ()-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.

The present invention encompasses an antithrombotic nanoparticle and use thereof.

The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

The present invention provides a conjugate comprising: (a) a cardiovascular disease (CVD)-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric ()-epigallocatechin gallate (OEGCG), and optionally (c) a CVD-treating molecule encapsulated in the inner shell. The present invention further provides a method for treating a CVD by administering an effective amount of the present nanoparticle composition to a subject. The CVD-targeting ligand targets the heart tissue and delivers active ingredients to heart tissue for treating cardiovascular diseases or conditions.